boxes as to the proof of protection against sars-cov-2 delta variant. there was one glaring missing check in previous iterations of this and that was in the j&j clinical effectiveness. next slide. i had showed you before this slide looking at data of immune responses in vitro and this was the j&j vaccine study, which showed that it elicits durable antibody and cellar responses against delta with minimal decreases for at least eight months after immunization. next slide. we now have a slide that recently -- a study that recently came out from south africa and other southern african countries. it's called the sisonke study including health care workers, this is real world effectiveness against delta with a 91 to 96%